The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of this study to assess the effectiveness of selenium compared to placebo in reducing the lymphedema in-patients with breast cancer. Secondary objectives are to assess the impact of selenium on patient's quality of life and to assess the incidence of adverse effects of selenium therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Collaborator: Princess Margaret Hospital, Canada
• Treatments: Selenious Acid; Selenium; Sodium Selenite

Criteria

Inclusion Criteria:

• patients with clinically documented lymphedema of upper limb secondary to breast cancer management (surgery - axillary nodal dissection, and radiotherapy)

• patients who have had other modalities of management can be included, e.g. physical therapy, pharmacological therapy

• ECOG performance 0-2

• informed consent

Exclusion Criteria:

• active cellulitis/skin infection of the limb

• venous thrombosis of the upper limbs

• active malignancy

• any other medical condition or congenital or traumatic injury involving either limb

• patients already on selenium medication

• patients participating in another clinical study related to lymphedema